- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05930093
Evaluer effektiviteten og sikkerheten til LivPhcD-kapsler i NAFLD-emner
Multisenter, randomisert, dobbeltblind, placebokontrollert studie for å evaluere effektiviteten og sikkerheten til LivPhcD-kapsler i NAFLD-emner
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.
There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.
LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Not Required For This Country
-
Taipei, Not Required For This Country, Taiwan, 221
- National Taiwan University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female between 20 and 75 years of age.
- Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
- Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
- CAP ≥ 238 db/m
- Fibro scan (transient elastography) F0~F3
Exclusion Criteria:
- Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
- Type 1 diabetes mellitus.
- History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
- Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
- Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
- Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
- Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
- Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
- Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
- Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
- Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
- History of HIV
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Placebo without active ingredient |
Placebo matching LivPhcD cap. |
|
Aktiv komparator: 2 cap.LivPhcD/per day
515mg/LivPhcD cap. 2 cap./per day |
2 caps. LivPhcD cap. after meal, once a day |
|
Aktiv komparator: 4 cap.LivPhcD/per day
515mg/LivPhcD cap. 4 cap./per day, BID |
4 caps. LivPhcD cap. after meal, BID |
|
Aktiv komparator: 6 cap.LivPhcD/per day
515mg/LivPhcD cap. 6 cap./per day, TID |
6 caps. LivPhcD cap. after meal, TID |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Reduction of Liver Fat
Tidsramme: 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter) |
36 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in liver fat at least 30% reduction
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat at least 1 stage reduction
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change of liver fat by CAP |
24 weeks and 36 weeks
|
|
Stable in liver fat
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 10% reduction
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 1 stage reduction
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Stable in liver fibrosis
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change of FIB-4 |
24 weeks and 36 weeks
|
|
Change in ALT
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of ALT |
24 weeks and 36 weeks
|
|
Change in AST
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AST |
24 weeks and 36 weeks
|
|
Change in GGT
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of GGT |
24 weeks and 36 weeks
|
|
Change in AP
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AP |
24 weeks and 36 weeks
|
|
Change in Bilirubin
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Bilirubin |
24 weeks and 36 weeks
|
|
Change in Triglyceride
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Triglyceride |
24 weeks and 36 weeks
|
|
Change in Total Cholesterol
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Total Cholesterol |
24 weeks and 36 weeks
|
|
Change in HDL-C
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of HDL-C |
24 weeks and 36 weeks
|
|
Change in LDL-C
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of LDL-C |
24 weeks and 36 weeks
|
|
Change in TNF-α
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of TNF-α |
24 weeks and 36 weeks
|
|
Change in C-Reactive Protein
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of C-Reactive Protein |
24 weeks and 36 weeks
|
|
Change in Albumin
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Albumin |
24 weeks and 36 weeks
|
|
Occurrence of adverse events and serious adverse events
Tidsramme: 24 weeks and 36 weeks
|
Between group difference in the occurrence of adverse events and serious adverse events. |
24 weeks and 36 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LivPhcD-001
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .